Biohaven (BHVN) Other Non-Current Liabilities (2021 - 2026)
Biohaven's (BHVN) quarterly Other Non-Current Liabilities came in at $4.6 million in Q1 2026, down 94.84% year-on-year from $88.3 million in Q1 2025, and down 0.59% quarter-over-quarter from $4.6 million in Q4 2025.
Biohaven (BHVN) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Biohaven has disclosed Other Non-Current Liabilities across 6 years of filings, most recently posting $4.6 million for Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $4.6 million, down 94.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.6 million (down 94.84% YoY), and the FY2025 annual result was $4.6 million, down 1.72% from the prior year.
- Other Non-Current Liabilities came in at $4.6 million for Q1 2026 at Biohaven, down from $4.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $268.3 million in Q3 2025 to a low of $2.2 million in Q4 2023.
- The 5-year median for Other Non-Current Liabilities is $4.6 million (2026), against an average of $43.9 million.
- Across the five-year window, Other Non-Current Liabilities surged 5849.32% in 2025 and tumbled 94.84% in 2026, its largest moves.
- Biohaven's Other Non-Current Liabilities stood at $2.4 million in 2022, then decreased by 6.85% to $2.2 million in 2023, then jumped by 107.71% to $4.7 million in 2024, then fell by 1.72% to $4.6 million in 2025, then declined by 0.59% to $4.6 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $4.6 million (Q1 2026), $4.6 million (Q4 2025), and $268.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Biohaven | 1.62 Bn | 1.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.56 Mn |
| Dec 31, 2025 | 4.58 Mn |
| Sep 30, 2025 | 268.27 Mn |
| Jun 30, 2025 | 257.07 Mn |
| Mar 31, 2025 | 88.32 Mn |
| Dec 31, 2024 | 4.66 Mn |
| Sep 30, 2024 | 4.59 Mn |
| Jun 30, 2024 | 4.32 Mn |
| Mar 31, 2024 | 3.41 Mn |
| Dec 31, 2023 | 2.25 Mn |
| Sep 30, 2023 | 2.27 Mn |
| Jun 30, 2023 | 2.52 Mn |
| Mar 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 2.41 Mn |
| Sep 30, 2022 | 7.00 Mn |
| Dec 31, 2021 | 2.64 Mn |